#USA #San Francisco #J.P. Morgan #Expression Therapeutics #David Townson

Expression Therapeutics to Shine at J.P. Morgan Healthcare Conference 2027

Expression Therapeutics, Inc., a pioneering clinical-stage biotechnology firm, has announced that its Chief Executive Officer, Dr. David F. Townson, will represent the company at the prestigious 45th Annual J.P. Morgan Healthcare Conference. Scheduled to take place from January 11 to January 14, 2027, in San Francisco, this gathering is renowned for assembling leading figures from the healthcare industry, including innovators, emerging entities, and investors.

A Platform for Collaborations

This key event serves as an exceptional opportunity for Expression Therapeutics to engage potential pharmaceutical partners. During the conference, Dr. Townson is expected to highlight the company's groundbreaking therapeutic programs focusing on hemophilia A and neuroendocrine tumors. The company is at the forefront of developing transformative alternatives to traditional treatment methods, which is paramount given the rising prevalence of these medical conditions.

Advancements in Hemophilia A Treatment

Expression Therapeutics has made significant inroads with its investigational treatments for hemophilia A, particularly noting its one-time therapy that leverages a patient's own blood stem cells to produce factor VIII. This groundbreaking therapy has shown remarkable outcomes in a Phase 1 study (NCT05265767), where patients with severe hemophilia A exhibited an unprecedented annualized bleeding rate of zero across a combined follow-up period of 81 months. The program has garnered Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA in April 2026, and plans for a Phase 2 study in the U.S. are underway for Q4 2027.

Targeting Neuroendocrine Tumors

The rise of neuroendocrine tumors in the U.S. — with approximately 244,000 individuals diagnosed in the past 20 years — emphasizes the urgent need for innovative treatments. Current therapies typically only slow tumor progression. Expression Therapeutics is addressing this challenge through its two preclinical cell therapies designed to enhance the activity of a patient's own gamma delta T cells. These therapies aim to localize T-cell response directly at tumor sites while minimizing exposure elsewhere in the body. One therapy, ET401, targets SSTR2 and has shown promise by reducing the viability of tumor spheroids in laboratory tests. A filing for Investigational New Drug (IND) application for ET401 is anticipated in Q4 2027, with a similar plan for ET501, designed for more aggressive neuroendocrine carcinomas and neuroblastomas, expected in Q1 2029.

Manufacturing Excellence

Expression Therapeutics prides itself on its advanced manufacturing capabilities, operating its own 43,000-square-foot GMP facility in Cincinnati, Ohio, where they produce both viral vectors and cell therapies. Dr. Townson emphasizes the significance of the J.P. Morgan Healthcare Conference, stating that it effectively brings together key decision-makers, thus fostering essential relationships for advancing their promising programs. He is set to bring forth solid clinical data showcasing durable safety and efficacy for their therapies, an instrumental factor in forging successful partnerships.

Conclusion

Expression Therapeutics continues to set a remarkable precedent in the biotechnology space, actively pursuing partnerships that could propel their research and therapies into broader clinical use. As they prepare for the J.P. Morgan Healthcare Conference, stakeholders within the industry are keenly observing this pivotal moment for the company, hoping to witness the potential evolution of treatment protocols for hemophilia and neuroendocrine tumors. For further details about Expression Therapeutics and its innovative pursuits, please visit www.expressiontherapeutics.com.